Achieve Life Sciences Inc
$ 6.77
1.50%
11 Aug - close price
- Market Cap 684,736,000 USD
- Current Price $ 6.77
- High / Low $ 6.95 / 6.53
- Stock P/E N/A
- Book Value 0.20
- EPS -1.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.08 %
- ROE -4.96 %
- 52 Week High 7.11
- 52 Week Low 2.45
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-24 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-11 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.19 | -0.28 | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 |
| Estimated EPS | -0.3 | -0.2771 | -0.26 | -0.37 | -0.37 | -0.36 | -0.29 | -0.24 | -0.25 | -0.31 | -0.37 | -0.41 |
| Surprise | 0.11 | -0.0029 | -0.02 | 0 | 0 | 0 | -0.07 | -0.01 | -0.01 | 0.05 | 0.03 | -0.02 |
| Surprise Percentage | 36.6667% | -1.0466% | -7.6923% | 0% | 0% | 0% | -24.1379% | -4.1667% | -4% | 16.129% | 8.1081% | -4.878% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-08-11 16:10:29
Achieve Life Sciences reported a net loss per share of $0.80 and a net loss of $74.8M for Q2 2026, as it continues to invest in its cytisinicline smoking cessation therapy. The company focuses on the North American and UK markets, and Wall Street analysts maintain a positive outlook with 11 buy ratings and 1 hold recommendation.
2026-08-11 14:10:29
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly earnings of $(0.28) per share, falling short of analysts' consensus estimates by $0.12. Despite missing earnings expectations, ACHV shares saw a slight increase of 0.7% to $6.71, and institutional investors collectively own a significant portion of the company. Analyst sentiment remains largely positive with a "Buy" rating and a $16.00 price target.
2026-08-11 12:10:29
Achieve Life Sciences announced its second-quarter 2026 financial results, highlighted by closing a private placement of up to $354 million. The company received a Complete Response Letter from the FDA for cytisinicline's NDA due to cGMP issues and incomplete labeling, but no deficiencies in clinical efficacy or safety were identified. Achieve plans to resubmit its NDA in Q4 2026, anticipating potential FDA approval in H1 2027, and has strengthened its leadership and manufacturing capabilities.
2026-08-11 06:10:29
Achieve Life Sciences (NASDAQ:ACHV) stock price recently crossed above its 200-day moving average, trading as high as $6.80 and closing at $6.67, significantly above the $4.88 average. Analysts maintain a "Buy" consensus with a $16 price target, citing the company's Q2 EPS beat and institutional investor interest. Achieve Life Sciences, a clinical-stage biotech company, focuses on developing cytisinicline for smoking cessation.
2026-08-10 13:41:22
William Blair analyst Brandon Vazquez downgraded PROCEPT BioRobotics (PRCT) to Hold, citing a $23.13 average price target with a 15.4% upside. In contrast, LifeSci Capital analyst Patrick Dolezal rated Achieve Life Sciences (ACHV) as a Buy with a $17.00 price target. The article provides analyst consensus ratings and price targets for both healthcare companies, highlighting differing outlooks on their stock performance.
2026-08-03 12:15:01
Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. These appointments aim to strengthen the company's manufacturing, supply chain, and quality functions as it prepares for the resubmission of its New Drug Application (NDA) for cytisinicline and its anticipated U.S. commercial launch. The move is strategic, bringing in seasoned leaders to manage the transition of cytisinicline finished product manufacturing to the United States.
